Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study-Reference-Cited by-同舟云学术

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study

Published:2014-09 Issue:10 Volume:15 Page:1119-1128
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Gadgeel Shirish M,Gandhi Leena,Riely Gregory J,Chiappori Alberto A,West Howard L,Azada Michele C,Morcos Peter N,Lee Ruey-Min,Garcia Linta,Yu Li,Boisserie Frederic,Di Laurenzio Laura,Golding Sophie,Sato Jotaro,Yokoyama Shumpei,Tanaka Tomohiro,Ou Sai-Hong Ignatius

Publisher

Elsevier BV

Subject

Oncology

Reference24 articles.

1. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

2. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer;Rikova;Cell,2007

3. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology;Ou;Oncologist,2012

4. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer;Kwak;N Engl J Med,2010

5. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study;Camidge;Lancet Oncol,2012

Cited by 633 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape;Cancer Treatment Reviews;2024-11

2. Prognosis evaluation and efficacy analysis of different treatment options for patients with visceral pleural invasion in stage IIA–IIB lung cancer;Discover Oncology;2024-09-13

3. FGFR2 promotes resistance to ALK tyrosine kinase inhibitors and its inhibition acts synergistically with lorlatinib in the treatment of ALK-expressing neuroblastoma;2024-09-10

4. Treatment Advances in Lung Cancer with Leptomeningeal Metastasis;Current Cancer Drug Targets;2024-09

5. Cancer-associated fibroblasts confer ALK inhibitor resistance inEML4-ALK-driven lung cancer via concurrent integrin and MET signaling;2024-08-28